
Author's Accepted Manuscript

A novel highly potent and selective 11β -hydroxysteroid dehydrogenase type 1 inhibitor, INU-101

Sung Pyo Hong, Dongoh Han, Ki-Ho Chang, Soon Kil Ahn



PII: S0014-2999(18)30450-3

DOI: https://doi.org/10.1016/j.ejphar.2018.08.005

Reference: EJP71930

To appear in: European Journal of Pharmacology

Received date: 8 February 2018 Revised date: 3 August 2018 Accepted date: 3 August 2018

Cite this article as: Sung Pyo Hong, Dongoh Han, Ki-Ho Chang and Soon Kil Ahn, A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101, *European Journal of Pharmacology*, https://doi.org/10.1016/j.ejphar.2018.08.005

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101

Sung Pyo Hong ^a, Dongoh Han ^b, Ki-Ho Chang ^b, Soon Kil Ahn ^{a,*}

^a Institute for New Drug Development, Division of Life Sciences, Incheon National University, Incheon, Republic of Korea

^b Ahn-gook pharm., 6F, G-Plus Kolon Digital tower 123, Digital-ro 26gil, Guro-gu, Seoul, Republic of Korea

* Corresponding author at: Division of Life Sciences, Incheon National University, Incheon, Republic of Korea. E-mail address: skahn@inu.ac.kr (S.K. Ahn).

Abstract

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a cortisol regenerating enzyme that amplifies tissue glucocorticoid levels, especially in the liver and adipose tissue. Knockout mice or a selective inhibitor of 11β-HSD1 improves metabolic syndrome parameters in preclinical models and human clinical trials. Here, we evaluated the therapeutic potential of INU-101, a potent and selective oral inhibitor of 11β-HSD1. The in vitro activity of 11β-HSD1 was measured using the homogeneous time-resolved fluorescence (HTRF) assay. Differentiated adipocytes were used to evaluate the cellular 11β-HSD1 activity. To determine the inhibitory effects on 11β-HSD1 in tissues, we performed ex vivo studies using liver and adipose tissue isolated from C57BL/6J mice and Cynomolgus monkeys. KKAy mice, *ob/ob*

Download English Version:

https://daneshyari.com/en/article/8528879

Download Persian Version:

https://daneshyari.com/article/8528879

<u>Daneshyari.com</u>